Articles 10 www.thelancet.com/diabetes-endocrinology   Published online April 4, 2014   http://dx.doi.org/10.1016/S2213-8587(14)70029-4chief investigator on a trial for Novo Nordisk. JH and JM are  employees of Bristol-Myers Squibb. MKB is an employee and stockholder of Eli Lilly. MET was an employee of Eli Lilly at the time of the study; holds stock in Eli Lilly; and is a paid consultant for AstraZeneca, Bristol-Myers Squibb, Merck Sharp and Dohme, CeQur, Proﬁ  l Institute San Diego, and Hanmi Pharmaceuticals. Acknowledgments The study was supported by Eli Lilly and Amylin Pharmaceuticals, a wholly-owned subsidiary of Bristol-Myers Squibb. Additional analyses were supported by Bristol-Myers Squibb and AstraZeneca. We thank the patients, investigators (appendix), and their staﬀ   for participating in the study. We also thank Sushma Soni (inScience Communications, Springer Healthcare), who provided medical writing support funded by Bristol-Myers Squibb and AstraZeneca. References